Codexis Announces the Election of New Directors at its Annual Meeting of Stockholders
June 16 2020 - 04:05PM
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company
and developer of high-performance enzymes, announces the election
of new independent directors, Alison Moore, Ph.D. and Stephen
Dilly, MBBS, Ph.D. at the company’s 2020 Annual Meeting of
Stockholders held earlier today.
“We are delighted to welcome these two highly qualified
professionals to our board, both of whom bring exceptional
experience in biotherapeutics development and commercialization at
a time when we are increasing our focus on this business segment,”
said Bernard J. Kelley, Codexis Chairman.
Dr. Moore brings to Codexis significant experience as a
biotechnology and pharmaceutical executive, including an extensive
background in biomanufacturing. She is Chief Technical Officer of
Allogene Therapeutics, a pioneering clinical-stage company
advancing CAR-T therapies. Prior to Allogene she spent a total of
20 years at Amgen, most recently as Senior Vice President, Process
Development, and including roles in Supply Chain and Manufacturing.
Dr. Moore also has experience at Genentech as a Director in
Chemistry, Manufacturing and Controls, and Regulatory Affairs. Dr.
Moore holds a bachelor’s degree in Pharmacology with Honors and a
Ph.D. in Cell Biology from Manchester University, England.
Dr. Dilly brings to Codexis three decades of executive
management experience overseeing the development and
commercialization of a range of novel therapeutics addressing
multiple human disease conditions within both smaller and larger
biotechnology companies. In May 2020 he was appointed CEO and
director of the drug development company Sierra Oncology, Inc.
(Nasdaq: SRRA). He previously served as CEO and director of Aimmune
Therapeutics from 2014 to 2018 where he led the company through its
successful IPO in 2015, and its landmark Phase 3 study for its lead
product, Palforzia™, in early 2018. Dr Dilly’s earlier
experiences include several tenures as CEO and director of private
companies, as well as executive roles at Chiron, Genentech,
SmithKline Beecham, and Pfizer. Dr. Dilly received an MBBS and a
Ph.D. in cardiac physiology from the University of London.
In addition to the election of Drs. Moore and Dilly, Codexis
stockholders also re-elected Dr. Patrick Yang earlier today to
continue to serve on the board.
About Codexis, Inc.Codexis is a leading protein
engineering company that applies its proprietary CodeEvolver®
technology to discover, develop and commercialize proteins for a
variety of applications, including as biocatalysts for the
commercial manufacture of pharmaceuticals and fine chemicals,
industrial enzymes, enzymes for use in molecular biology,
diagnostics and other life science applications, and enzymes and
other proteins as biotherapeutics. Codexis’ proven technology
platform delivers value by enabling highly targeted and
application-relevant improvements in protein performance. For more
information, see www.codexis.com.
Forward-Looking StatementsTo the extent that
statements contained in this press release are not descriptions of
historical facts regarding Codexis, they are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. You should not
place undue reliance on these forward-looking statements because
they involve known and unknown risks, uncertainties and other
factors that are, in some cases, beyond Codexis’ control and that
could materially affect actual results. Factors that could
materially affect actual results include, among others: Codexis’
dependence on its licensees and collaborators; Codexis’ dependence
on a limited number of products and customers; and potential
adverse effects to Codexis’ business if its products are not
received well in the markets. Additional information about factors
that could materially affect actual results can be found in
Codexis’ Annual Report on Form 10-K filed with the Securities and
Exchange Commission (“SEC”) on February 28, 2020 and Form 10-Q
filed with the SEC on May 8, 2020, including under the caption
“Risk Factors” and in Codexis’ other periodic reports filed with
the SEC. Codexis expressly disclaims any intent or obligation to
update these forward-looking statements, except as required by
law.
Contact:LHA Investor RelationsJody
Cain310-691-7100jcain@lhai.com
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/18fa030d-90cc-4d54-9f1a-3e620d6ec3c6
https://www.globenewswire.com/NewsRoom/AttachmentNg/5eb9f535-d53c-4b2c-b3ff-975e5d8a17b9
Sierra Oncology (NASDAQ:SRRA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sierra Oncology (NASDAQ:SRRA)
Historical Stock Chart
From Mar 2023 to Mar 2024